WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?

Key Takeaways WVE surged after interim data showed significant visceral fat reduction with WVE-007.The drug also delivered statistically significant lean mass gains and was well-tolerated.Wave Life Sciences plans more INLIGHT cohort readouts through the first half of 2026.Shares of Wave Life Sciences (WVE) have soared 183% in the past week after the company reported encouraging interim data from an early-stage study evaluating its investigational weight-loss drug, WVE-007.Data from this study (called INLIGH ...